The P2X5 receptor (P2X5R) is a member of the P2X family of ATP-gated ion channels, encoded by the P2RX5 gene. Unlike other P2X receptors, P2X5 exhibits unique pharmacological properties, including sensitivity to certain antagonists and modulators, and is expressed in specific tissues including lymphoid organs, bladder, and selective neuronal populations. Recent research suggests potential roles for P2X5 in neuroimmune signaling and neurodegenerative processes[1][2].
P2X5 receptor is a ligand-gated ion channel that responds to extracellular adenosine triphosphate (ATP). It forms functional homotrimers (and possibly heterotrimers with other P2X subunits) that gate cations upon ATP binding. The receptor is characterized by relatively slow desensitization kinetics compared to P2X1 and P2X3, making it suitable for sustained signaling responses[1:1].
P2X5R contains:
| Property | Value |
|---|---|
| Subunit size | ~422 amino acids |
| Ion selectivity | Non-selective cation channel |
| Permeability | Na⁺, K⁺, Ca²⁺ |
| ATP EC₅₀ | ~10-30 μM |
| Desensitization | Slow |
High expression in:
In the CNS and PNS:
P2X5 may contribute to AD pathophysiology:
In PD:
P2X5 participates in neuroimmune crosstalk:
P2X5 is a potential therapeutic target for:
Current drug development focuses on:
The study of P2X5 Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.